Fundamental Analysis of AZIYO BIOLOGICS INC-CLASS A(NASDAQ:AZYO) stock

Fundamental Rating

Overall AZYO gets a fundamental rating of 1 out of 10. We evaluated AZYO against 588 industry peers in the Biotechnology industry. AZYO may be in some trouble as it scores bad on both profitability and health. AZYO has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AZYO has reported negative net income.

In the past year AZYO has reported a negative cash flow from operations.

AZYO had negative earnings in each of the past 5 years.

In the past 5 years AZYO always reported negative operating cash flow.

1.2 Ratios

AZYO has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AZYO's Gross Margin of 35.86% is fine compared to the rest of the industry. AZYO outperforms 75.90% of its industry peers.

AZYO's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for AZYO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	35.86%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.35%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AZYO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for AZYO has been increased compared to 1 year ago.

AZYO has a worse debt/assets ratio than last year.

2.2 Solvency

AZYO has an Altman-Z score of -4.75. This is a bad value and indicates that AZYO is not financially healthy and even has some risk of bankruptcy.

AZYO has a Altman-Z score of -4.75. This is in the lower half of the industry: AZYO underperforms 66.15% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-4.75

ROIC/WACCN/A

WACC16.57%

2.3 Liquidity

AZYO has a Current Ratio of 0.84. This is a bad value and indicates that AZYO is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.84, AZYO is not doing good in the industry: 92.99% of the companies in the same industry are doing better.

AZYO has a Quick Ratio of 0.84. This is a bad value and indicates that AZYO is not financially healthy enough and could expect problems in meeting its short term obligations.

AZYO's Quick ratio of 0.63 is on the low side compared to the rest of the industry. AZYO is outperformed by 94.70% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.84
Quick Ratio	0.63

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.95% over the past year.

AZYO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.13%.

The Revenue has been growing slightly by 4.66% on average over the past years.

EPS 1Y (TTM)22.95%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q5.8%

Revenue 1Y (TTM)4.13%

Revenue growth 3Y4.66%

Revenue growth 5YN/A

Revenue growth Q2Q-18.53%

3.2 Future

AZYO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.

Based on estimates for the next years, AZYO will show a small growth in Revenue. The Revenue will grow by 2.27% on average per year.

EPS Next Y9.47%

EPS Next 2Y17.99%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-12.95%

Revenue Next 2Y2.27%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AZYO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AZYO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AZYO's earnings are expected to grow with 17.99% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.99%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AZYO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AZIYO BIOLOGICS INC-CLASS A

NASDAQ:AZYO (9/6/2023, 7:00:01 PM)

1.49

+0.03 (+2.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap24.21M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	35.86%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.92

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.84
Quick Ratio	0.63
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)22.95%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y9.47%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)4.13%

Revenue growth 3Y4.66%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

AZIYO BIOLOGICS INC-CLASS A (AZYO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens